 |
Self
Study Program based on a Satellite Symposium of the American Society
of Nephrology 33rd Annual Scientific Meeting, October, 2000
This
program is sponsored by Tufts University School of Medicine. This
is not part of the official 33rd Annual Meeting as planned by
the ASN Program Committee. Supported by an unrestricted educational
grant from Amgen Inc.
To
access this self study program at no charge please click
here to register first with HDCN. This program offers 2.0
hours of Category One CME Credit for Physicians by Tufts University
School of Medicine.
Overall Program Goal and Educational Objectives
For reasons that are not clearly understood, the number of people
with end-stage renal disease (ESRD) is growing. This has led to
an increased recognition of the need for early identification
of patients with chronic kidney disease. The magnitude of the
population with chronic renal insufficiency (CRI) or who are at
risk for CRI is just beginning to be appreciated. According to
data from the Third National Health and Nutrition Examination
Survey (NHANES III), 10.9 million Americans have serum creatinine
values of 1.5 mg/dL or greater.
Many CRI patients develop anemia, which is underrecognized and
undertreated. In one study, 68% of patients at the initiation
of dialysis were severely anemic. With early identification of
CRI, the clinician can develop strategies to prevent or delay
adverse sequelae. Late referral and poor preparation for renal
replacement therapy are associated with poorer long-term outcomes.
Data suggest that anemia left untreated can result in poor patient
outcomes and debilitating complications.
The risk of left ventricular hypertrophy increases as hemoglobin
(Hb) levels fall. For every 0.5 g/dL decrease in Hb, relative
left ventricular growth increases by 32%. Thirty-five percent
of ESRD patients are diabetics, and 25% to 30% have hypertension,
constituting two groups that are identifiable early in the disease
process. Furthermore, hematocrit levels correlate with health-related
quality-of-life assessments.
Overall, evidence suggests that a focus on prevention and early
intervention is likely to be fruitful, reducing the number of
patients whose disease proceeds to end stages. Further research,
however, is needed.
 |
An
Overview of CRI and Anemia in the United States - Underrecognized
and Undertreated
Brian Pereira, M.D.. |
|
Panel
Discussion (video and FAQ mode)
Allen Nissenson, M.D., Roger London, M.D., Steven Fishbane,
M.D. |
|
Emerging
Data on LVH, Cardiovascular Disease, and Anemia
Adeera Levin, M.D. |
|
Adverse
Sequelae of Anemia: More than just Cardiovascular
David Churchill, M.D. |
|
Entire
Group Panel Discussion (video and FAQ mode)
Drs. Pereira, Nissenson, London, Fishbane, Levin, and Churchill |
|
Brian Pereira,
M.D., Symposium Chairman. Professor of Medicine, Tufts University
School of Medicine; Vice Chairman for Strategic Development in the
Department of Medicine at New England Medical Center, Boston, MA
David Churchill, M.D., Professor of Medicine in the Faculty
of Health Sciences at McMaster University in Hamilton, Ontario,
Canada.
Steven Fishbane, M.D., Associate Professor of Medicine, State
University of New York at Stony Brook School of Medicine; Director
of the Dialysis Network, Associate Chairman of Medicine, and Associate
Director of Nephrology at Winthrop University Hospital, Mineola,
NY.
Adeera Levin, M.D., Clinical Associate Professor of Medicine,
University of British Columbia, Vancouver, Canada.
Roger London, M.D., Assistant Clinical Professor of Medicine, Mount Sinai School
of Medicine, New York City; Senior Regional Medical Director for
New York, Oxford Health Plans, Norwalk, CT
Allen Nissenson, M.D., Professor of Medicine, University
of California at Los Angeles School of Medicine; Director of the
Dialysis Program at the UCLA Center for the Health Sciences, Los
Angeles, CA . |
| In accord
with the policies of Tufts University School of Medicine (TUSM)
Office of Continuing Education and the Essential Areas and Policies
and Standards of the Accreditation Council for Continuing Medical
Education (ACCME), the ethical opinions of the American Medical
Association (AMA), the Guidelines of the Pharmaceutical Research
Manufacturers Association (PhRMA), the American Nurses Credentialing
Center's Commission on Accreditation (ANCC), the American Council
on Pharmaceutical Education (ACPE), and all other professional organizations
as applicable, all programs offered by TUSM shall exhibit fair content
balance, providing the audience with information of different perspectives
from which to develop an informed opinion.
All faculty
participating in any TUSM sponsored/cosponsored program are expected
to disclose to the audience any real or apparent conflict(s) of
interest during the past two years that may have a direct bearing
on the subject matter of the continuing education program. This
pertains to relationships with pharmaceutical companies, biomedical
device manufacturers, or other corporations whose products or
services are related to the therapeutic areas to be discussed.
Accreditation
Tufts University School of Medicine (TUSM) is accredited by the
Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians. TUSM takes
responsibility for the content, quality, and scientific integrity
of this Continuing Education activity.
TUSM designates
this educational activity for a maximum of two (2) hours in Category
I credit towards the AMA Physician's Recognition Award. Each physician
should claim only those hours of credit that he/she actually spent
in the educational activity.
In order
to successfully complete this activity, you are required to read
or listen to the entire web-based presentation, legibly complete
the Post-Test/Evaluation
Form, and achieve a minimum passing grade of at least 70%
on the Post-Test. The Post-Test and Evaluation Form must be sumitted
by December 31, 2002.
Fax the completed
Post-Test/Evaluation
Form to 617-636-0472 or mail to Tufts University School of Medicine,
Office of Continuing Education, 136 Harrison Ave., Boston, MA
02111. Certificates will be mailed within 4-6 weeks after receipt
to those who successfully complete the Post-Test/Evaluation form.
There is no registration fee to participate in this activity.
TUSM Conflict
of Interest Policy
It is intended that any potential conflict should be identified
openly so that the listeners may form their own judgements about
the presentation(s) with full disclosure of the facts. It remains
for the audience to determine whether the outside interests of
the faculty reflect a possible bias in either the materials or
the conclusions presented. The opinions and recommendations presented
do not necessarily reflect the views of the sponsor, grantor,
or producer.
Indications
and methods of use for pharmaceutical agents and other products
in this program may not be necessarily the same as those indicated
in the package insert for the product and may reflect the clinical
experience, the professional literature or other clinical sources.
The faculty
listed below provided the following information:
| NAME |
TYPE OF AFFILIATION |
COMMERCIAL ENTITY |
| Brian Pereira |
Grant/Research Support |
Amgen |
| |
Consultant |
Amgen, Baxter |
| |
Speakers' Bureau |
Amgen |
| |
| David Churchill |
Consultant |
Amgen |
| |
| Steven Fishbane |
Grant/Research Support |
Amgen |
| |
Consultant |
Amgen |
| |
Speakers' Bureau |
Amgen |
| |
| Adeera Levin |
Grant/Research Support |
Janssen, Ortho, Baxter |
| |
Consultant |
Janssen, Ortho, Genzyme,
Amgen |
| |
Speakers' Bureau |
Amgen |
| |
| Roger London |
Consultant |
Amgen |
| |
| Allen Nissenson |
Grant/Research Support |
Amgen, Schein |
| |
Consultant |
Amgen, Schein |
| |
Speakers' Bureau |
Amgen, Schein |
|
|
|
|
This
is not part of the official 33rd Annual Meeting as planned
by the ASN Program Committee.
Supported by an unrestricted educational grant from Amgen,
Inc.
|
|
|
|
